Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups

Eisemann, C S; Fisher, Susan G.; Gross, Gerd; Müller, Martin; Gissmann, Lutz

doi:10.1099/0022-1317-77-8-1799

Cited by 20 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data from Western Europe were available from Austria (42-45), Finland (46-51), Germany (52-54), Italy (40,55), The Netherlands (10,40,56), Norway (57,58), Spain (16,59), Sweden (60-69) and the United Kingdom (70,71). The only studies from Eastern Europe were from the Czech Republic (72-74).…”

Section: Resultsmentioning

confidence: 99%

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Tiggelaar¹,

Lin²,

Viscidi³

et al. 2012

Journal of Adolescent Health

View full text Add to dashboard Cite

Purpose Global data on human papillomavirus serological and DNA prevalence are essential to optimize HPV prophylactic vaccination strategies. Methods We conducted a global review of age-specific HPV antibody and studies with both antibody and DNA prevalence for HPV types 16, 18, 6 and 11. Results One hundred-seventeen studies were included; participants’ ages ranged from several hours to over 90 years. HPV 16 seroprevalence was generally higher in Africa, Central and South America, and North America, more prevalent among women than men, and peaked around ages 25-40 years. HPV 18 seroprevalence was generally lower than HPV 16 with a later age peak. Data were limited for HPV 6 and 11, which both peaked at ages similar to HPV 18. In 9-26 year-old females, HPV 16 seroprevalence ranged from 0-31% in North America, 21-30% in Africa, 0-23% in Asia/Australia, 0-33% in Europe, and 13-43% in Central and South America. HPV 16/18 DNA prevalence peaked 10-15 years before corresponding HPV 16/18 antibody prevalence. Conclusions Females within the HPV-vaccine eligible age group (9-26 years) had a range of dual HPV 16 DNA and serology negativity from 81-87%, whereas 90-98% were HPV 16 DNA negative. Serology and DNA data are lacking worldwide for females younger than age 15 years, the prime target group for vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Tiggelaar¹,

Lin²,

Viscidi³

et al. 2012

Journal of Adolescent Health

View full text Add to dashboard Cite

show abstract

“…The researchers showed that the average ELISA value for women with warts was significantly greater than that for men, and that the number of sex partners was associated with ELISA reactivity for women. Eisemann et al 35 also detected a sex diVerence for antibodies to HPV 11 capsids in control groups consisting of hospitalised individuals without known HPV infections and blood donors without information on HPV infection, but not in patients with condylomata acuminata. Recently, lower seroreactivity to HPV 16 virus-like particles in men attending STD clinics in Denmark and Greenland compared with seroreactivity in women attending the same clinics was reported by Svare et al 36 As possible explanations biological diVerences-for example, the area of aVected mucosal surface, and variables related to sexual life were given.…”

Section: Discussionmentioning

confidence: 97%

Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection.

et al. 1998

View full text Add to dashboard Cite

Objectives: We performed a study to establish the pattern of serological reactivity for immunoglobulins (Ig), to capsids of human papilloma virus (HPV) after new HPV infection in two groups of subjects. Methods: The pattern of serological reactivity after acquisition of infection with HPV was investigated by measuring IgA, IgM, and IgG antibodies to capsids containing L1 and L2 proteins of HPV types 6, 11, 16, 18, and 33 in longitudinal studies of groups with diVerent patterns of sexual activity. Individuals who tested negative for HPV DNA by the polymerase chain reaction at enrolment, but who became HPV DNA positive during follow up, were examined for antibodies to HPV capsids by enzyme linked immunosorbent assay. One group consisted of 15 young girls (with eight controls who remained HPV DNA negative) who were becoming sexually active and the other comprised 12 male (with five controls) and 35 female (with seven controls) heterosexual attenders of a sexually transmitted disease clinic who had had multiple sexual partners. Results: The sexually inexperienced girls showed IgA and IgG responses, but seldom an IgM response to infection with HPV types 6/11, 16, and 18. No consistent pattern of serological reactivity was apparent for the heterosexuals with multiple partners. The lack of association between current HPV DNA positivity and detectable antibodies in these individuals was possibly related to the duration of infection or to prior exposure to HPV. For the latter group serological reactivity to HPV capsids was significantly greater in women than in men (p =0.001, p = 0.003, and p = 0.024, for IgG to HPV 6, 11, and 16, respectively). Conclusion:The sex diVerence in antibody response detected in previous studies with assays based on peptide antigens was thus corroborated in the present study with capsid based serological assays. This sex diVerence might reflect a diVerence in sexual activity and prior exposure to HPV between men and women in this particular group. (Sex Transm Inf 1998;74:354-360)

show abstract

“…There fore, we analyzed in parallel a panel of 75 sera obtained from healthy adult males. These sera had been collected as controls in a previous study and were found to be of low reactivity in an ELISA that was designed to measure anti bodies to HPV 11 VLP [10]. As their reactivity to all HPV-16-specific peptides used in this study proved to be low, too ( fig.…”

Section: Resultsmentioning

confidence: 99%

“…Sera from healthy adults attending the Department of Dermatology at the Hamburg University Hospital. Hamburg, Germany, because of fer tility problems [10] were found to be of low reactivity to the HPV-16-specific peptides and were thus used as controls to calculate the cut-off values (see below).…”

Section: Collection O F Specimensmentioning

confidence: 99%

Detection of Human Papillomavirus Type 16 DNA and of Antibodies to Human Papillomavirus Type 16 Proteins in Children

et al. 1997

Self Cite

View full text Add to dashboard Cite

We have measured markers of human papillomavirus type 16 (HPV 16) infection in children (1–10 years of age) who were hospitalized for reasons unrelated to papillomavirus infection. Genital and buccal swabs obtained from 79 children were tested for the presence of HPV 16 DNA by PCR. Low-level positivity was found in 34 donors, twice as often in oral than in genital swabs. There was no sex-specific difference, but there was a trend towards a higher positivity rate with young age. Serum antibodies (IgG) were measured by ELISA based on peptides derived from the HPV 16 early proteins E4 (one peptide), E6 (two peptides) or E7 (two peptides) in 75 children and by ELISA based on virus-like particles in 66 children. Low-positivity rates were found for E6 (5.1%), E7 (2.5%) or capsid proteins (1.5%), but 20.3% of the sera reacted with the E4-specific peptide. There was no correlation between sero-positivity and the detection of HPV 16 DNA. In those instances where HPV DNA positivity in young children represents true infection and not environmental contamination, we speculate that this infection is accompanied by low-level virus replication that does not induce a measurable antibody response. Reactivity to the E4 protein is likely due to cross-reacting antibodies directed either against E4 proteins of other HPV types or against unrelated antigens.

show abstract

Antibodies to human papillomavirus type 11 virus-like particles in sera of patients with genital warts and in control groups

Cited by 20 publications

References 14 publications

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Age-Specific Human Papillomavirus Antibody and Deoxyribonucleic Acid Prevalence: A Global Review

Immunoglobulin A, G, and M responses to L1 and L2 capsids of human papillomavirus types 6, 11, 16, 18, and 33 L1 after newly acquired infection.

Detection of Human Papillomavirus Type 16 DNA and of Antibodies to Human Papillomavirus Type 16 Proteins in Children

Contact Info

Product

Resources

About